Education
About Us
Working with TipRanks
Follow Us
AN2 Therapeutics, Inc. (ANTX)
:ANTX
ANTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.87 - $3.07
Previous CloseN/A
Volume42.38K
Average Volume (3M)264.00K
Market Cap
$34.40M
Enterprise Value$283.72M
Total Cash (Recent Filing)$67.06M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Aug 07, 2025EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding30,175,720
10 Day Avg. Volume253,630
30 Day Avg. Volume264,002
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)59.96
Price to Sales (P/S)0.00
P/FCF Ratio-116.09
Enterprise Value/Market Cap8.25
Enterprise Value/Revenue1.77K
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.59
Forecast
1Y Price Target
$1.67Price Target Upside46.49% Upside
Rating ConsensusHold
Number of Analyst Covering4
AN2 Therapeutics, Inc. News
PremiumCompany Announcements
AN2 Therapeutics Unveils Updated Investor Presentation
PremiumCompany Announcements
AN2 Therapeutics Elects New Directors at Annual Meeting
PremiumCompany Announcements
AN2 Therapeutics Faces Setback in Phase 3 Study
Bulls Say, Bears Say
Bulls Say
Drug EfficacyThe efficacy of oral epetraborole is supported by positive patient-reported outcomes and clean safety results.
Financial StabilityCash, cash equivalents, and investments totaled $78.5M, anticipated to fund operations into 2028.
Pipeline DevelopmentANTX plans to use non-dilutive funding to help advance epetraborole for the treatment of non-tuberculous mycobacterial (NTM) lung disease caused by M. abscessus.
Bears Say
Clinical Trial ResultsThe final shoe has dropped for AN2 Therapeutics' epetraborole program in refractory MAC lung disease, as the EBO-301 Ph.3 study missed the primary endpoint.
Trial ChallengesThe key secondary endpoint of sputum culture conversion was not met; 6-month culture conversion was similar between arms.
Trial DiscontinuationAN2 terminated both the Ph2 and Ph3 parts of the EBO-301 trial.
ANTX FAQ
What was AN2 Therapeutics, Inc.’s price range in the past 12 months?
AN2 Therapeutics, Inc. lowest stock price was $0.87 and its highest was $3.07 in the past 12 months.
What is AN2 Therapeutics, Inc.’s market cap?
AN2 Therapeutics, Inc.’s market cap is $34.40M.
When is AN2 Therapeutics, Inc.’s upcoming earnings report date?
AN2 Therapeutics, Inc.’s upcoming earnings report date is Aug 07, 2025 which is in 53 days.
How were AN2 Therapeutics, Inc.’s earnings last quarter?
AN2 Therapeutics, Inc. released its earnings results on May 07, 2025. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.265 by -$0.085.
Is AN2 Therapeutics, Inc. overvalued?
According to Wall Street analysts AN2 Therapeutics, Inc.’s price is currently Undervalued.
Does AN2 Therapeutics, Inc. pay dividends?
AN2 Therapeutics, Inc. does not currently pay dividends.
What is AN2 Therapeutics, Inc.’s EPS estimate?
AN2 Therapeutics, Inc.’s EPS estimate is -0.31.
How many shares outstanding does AN2 Therapeutics, Inc. have?
AN2 Therapeutics, Inc. has 30,175,720 shares outstanding.
What happened to AN2 Therapeutics, Inc.’s price movement after its last earnings report?
AN2 Therapeutics, Inc. reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.265. Following the earnings report the stock price went down -1.613%.
Which hedge fund is a major shareholder of AN2 Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ANTX
AN2 Therapeutics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.67 (46.49% Upside)
$1.67 (46.49% Upside)
Hedge Fund Trend
Decreased
By 2.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.45%
12-Months-Change
Fundamentals
Return on Equity
-49.32%
Trailing 12-Months
Asset Growth
-32.92%
Trailing 12-Months
Company Description
AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. (ANTX) is a biopharmaceutical company focused on developing novel treatments for rare, chronic, and serious infectious diseases. The company operates within the healthcare and biotechnology sectors, leveraging advanced scientific research to address unmet medical needs. AN2 Therapeutics is primarily engaged in the research, development, and commercialization of therapeutic products, particularly targeting conditions that lack effective treatment options.
ANTX Stock 12 Month Forecast
Average Price Target
$1.67
▲(46.49%Upside)
Technical Analysis
Dyadic International
―
Outlook Therapeutics
―
Spero Therapeutics
―
X4 Pharmaceuticals
―
Iterum Therapeutics
―